作者: Zammam Areeb , Stanley S. Stylli , Rachel Koldej , David S. Ritchie , Tali Siegal
DOI: 10.1007/S11060-015-1912-0
关键词:
摘要: Glioblastoma is the most aggressive and lethal tumour of central nervous system as such identification reliable prognostic predictive biomarkers for patient survival recurrence paramount. MicroRNA detection has rapidly emerged potential biomarkers, in patients with glioblastoma. Over last decade, analysis miRNA laboratory based studies have yielded several candidates however, accepted use these clinic yet to be validated. Here we will examine signatures improve glioblastoma stratification into subgroups summarise recent advances made examination progression recurrence.